CHMP wants to expand use of BV to include CTCL

Print Friendly, PDF & Email


Micrograph showing
mycosis fungoides
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the approved indication for brentuximab vedotin (BV, Adcetris). The CHMP is recommending authorization of BV to treat adults with CD30+ cutaneous T-cell lymphoma (CTCL) who have received at least 1 prior systemic therapy. The... [Read Article]
Print Friendly, PDF & Email

FDA approves brentuximab vedotin for pcALCL, MF

Print Friendly, PDF & Email


Brentuximab vedotin
Photo from Business Wire
The US Food and Drug Administration (FDA) has expanded the approved use of brentuximab vedotin (BV, ADCETRIS). BV is now approved for adults with primary cutaneous anaplastic large-cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy. This is the fourth FDA-approved indication for... [Read Article]
Print Friendly, PDF & Email

Ibrutinib sustains efficacy in CLL at 4-year follow-up

Print Friendly, PDF & Email


Ibrutinib (Imbruvica)
Photo courtesy of Janssen
The 4-year follow-up of the RESONATE trial suggests ibrutinib may provide long-term efficacy in previously treated patients with chronic lymphocytic leukemia (CLL). The median progression-free survival (PFS) has not yet been reached in this trial, regardless of high-risk cytogenetics, according to Jennifer Brown, MD, PhD, of the Dana-Farber... [Read Article]
Print Friendly, PDF & Email

Intervention improves well-being in AYAs with cancer

Print Friendly, PDF & Email


Doctor consults with cancer patient and her father
Photo by Rhoda Baer
New research suggests an intervention can improve psychosocial health in adolescents and young adults (AYAs) living with cancer. The intervention, Promoting Resilience in Stress Management (PRISM), is designed to help patients manage stress, set goals, and change their perspective. Overall, PRISM improved... [Read Article]
Print Friendly, PDF & Email

FDA approves drug to treat rel/ref MCL

Print Friendly, PDF & Email


Acalabrutinib (Calquence)
Photo from AstraZeneca
The US Food and Drug Administration (FDA) has granted accelerated approval to the BTK inhibitor acalabrutinib (Calquence, formerly ACP-196). The drug is now approved to treat adults with mantle cell lymphoma (MCL) who have received at least 1 prior therapy. The FDA’s accelerated approval pathway is used for... [Read Article]
Print Friendly, PDF & Email